
Mohamad Ali Najia
Research Fellow focused on hematopoiesis, genomics, and synthetic biology
Summary
Work
Education
Projects
Writing
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers
January 1, 2025Preprint reporting that inhibition of H3K9 demethylases KDM4A/C disrupts heterochromatin fidelity, induces replication stress and cGAS-STING signaling, and identifies KDM4 inhibition as a potential therapeutic vulnerability across lymphomas and other cancers.
Live-cell transcriptomics with engineered virus-like particles
October 1, 2024Preprint describing a synthetic RNA export system enabling live-cell, transcriptome-scale profiling by packaging cellular RNAs into engineered virus-like particles for extracellular capture and analysis.
EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
August 1, 2022Journal article demonstrating that EZH1 repression facilitates in vitro differentiation and maturation of T cells from iPSCs and that EZH1-repressed iPSC-derived T cells (EZ-T cells) can produce developmentally mature T cells with diverse TCR repertoires and potent antitumor activity when engineered as CAR T cells.
CellComm infers cellular crosstalk that drives haematopoietic stem and progenitor cell development
April 1, 2022Nature Cell Biology paper describing CellComm, an algorithm to infer intercellular communication and downstream signalling from single-cell and spatial transcriptomics, and its application to identify niche signals regulating HSPC emergence.